Constructive Bio Secures $58 Million Series A Funding
Constructive Bio, a pioneering synthetic genomics company located in Cambridge, UK, has successfully raised a remarkable $58 million in Series A funding. This significant funding round was led by prominent investors including Ahren, OMX Ventures, and Paladin Capital Group, and was further bolstered by contributions from Fine Structure Ventures, +ND Capital, and investor Jonathan Milner. With this latest infusion of capital, the total amount raised by Constructive Bio to date has reached an impressive $75 million. The company aims to utilize these funds to propel the development of its groundbreaking technology, which focuses on writing genomes from scratch and creating entirely new biomolecules that could revolutionize various industries.
Under the leadership of CEO Ola Wlodek and CSO and Founder Professor Jason Chin, Constructive Bio has made remarkable strides in advancing its innovative technology.
The company's unique approach allows it to transform living cells into biofactories, enabling the production of sustainable new materials and advanced therapeutics. By employing genome synthesis, Constructive Bio can meticulously write complete custom genomes, exercising full control over both the genetic sequence and the encoded information. This capability, combined with engineered protein translation, facilitates the creation and biomanufacturing of entirely new molecules with distinct characteristics and functionalities, positioning the company at the forefront of synthetic biology.
Since its inception in 2022, Constructive Bio has made impressive progress in unlocking the commercial potential of its proprietary platforms. The company has been actively optimizing its synthetic organisms, demonstrating the scalable production of multi-functionalized proteins at commercial titres. As a result, Constructive Bio now possesses the capability to introduce new products and manufacturing methodologies across a diverse range of sectors, encompassing pharmaceuticals, chemicals, materials, and consumer goods. This expansion into various industries underscores the transformative potential of its technologies and marks a significant step toward achieving sustainability and innovation in biotechnology.
They've invested in Constructive Bio
Get to know these Biotech investors
Click here for a full list of 6,312+ startup investors in the UK